>>> US Research Calls

Research Calls
  • Upgrades
    • Amazon (AMZN) upgraded to Overweight from Equal Weight at Wells Fargo, tgt $280
    • General Motors (GM) upgraded to Buy from Neutral at UBS, tgt $81
    • LTC Properties (LTC) upgraded to Market Perform from Underperform at BMO Capital, tgt $39
    • Micron (MU) upgraded to Outperform from Neutral at KGI Securities, tgt $196
    • Prestige Consumer (PBH) upgraded to Buy from Neutral at Sidoti; tgt $80
    • Quanta Services (PWR) upgraded to Buy from Hold at Jefferies, tgt $469
    • ServiceNow (NOW) upgraded to Overweight from Equal Weight at Morgan Stanley, tgt $1,250
    • Valley National Bancorp (VLY) upgraded to Buy from Hold at Jefferies, tgt $14
    • Vor Biopharma (VOR) upgraded to Buy from Hold at Stifel, tgt $55
  • Downgrades
    • Adobe (ADBE) downgraded to Equal Weight from Overweight at Morgan Stanley, tgt $450
    • Arvinas (ARVN) downgraded to Neutral from Buy at BofA Securities, tgt $10
    • Bloom Energy (BE) downgraded to Underperform from Hold at Jefferies, tgt $31
    • CrowdStrike (CRWD) downgraded to Sell from Hold at DZ Bank, tgt $440
    • Keurig Dr Pepper (KDP) downgraded to Equal Weight from Overweight at Barclays, tgt $26
    • Knight-Swift (KNX) downgraded to Neutral from Positive at Susquehanna, tgt $43
  • Others
    • Assembly Biosciences (ASMB) initiated with an Outperform at Citizens JMP, tgt $38
    • Axon Enterprise (AXON) initiated with an Overweight at Piper Sandler, tgt $893
    • Cipher Mining (CIFR) initiated with a Buy at Arete, tgt $24
    • DiDi Global (DIDIY) initiated with an Overweight at JPMorgan, tgt $10
    • IREN Ltd. (IREN) initiated with a Buy at Arete, tgt $78
    • Mirum Pharmaceuticals (MIRM) initiated with a Buy at TD Cowen, tgt $95
    • Motorola Solutions (MSI) initiated with a Neutral at Piper Sandler, tgt $495
    • Oddity Tech (ODD) initiated with a Buy at Jefferies, tgt $78
    • Ocean Power (OPTT) initiated with a Buy at Ladenburg Thalmann, tgt 1.50
    • Packaging Corp. (PKG) initiated with an Overweight at JPMorgan, tgt $242
    • Resources Connection (RGP) initiated with a Buy at Northcoast Research, tgt $7
    • Riot Platforms (RIOT) initiated with a Buy at Arete, tgt $26
    • Sana Biotechnology (SANA) initiated with an Outperform at Wedbush, tgt $5
    • The Vita Coco Co. (COCO) initiated with a Hold at Needham

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • MU -1.1% (also partnering with TSM to manufacture HBM4 base logic die), WOR -0.5%, AIR -0.5%
Other news:
  • COHU -9.6% ($200 mln convertible notes offering)
  • CTRE -3% (CFO to retire, names new CFO)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • THO +5.1%, MLKN +2.9%
Select lithium names showing strength in sympathy with LAC:
  • SLI +6.3%, SGML +4.8%, ALB +4%, SQM +3%
Other news:
  • LAC +68.4% (Trump administration is seeking an equity stake of as much as 10%, according to Reuters)
  • CLCO +19.3% (agrees in principle for potential combination of CoolCo and EPS Ventures)
  • BABA +9.1% (unveils strategic roadmaps for the next generation AI innovations)
  • MIR +7.7% (to acquire Paragon Energy Solutions from Windjammer Capital Investors for approximately $585 million in cash; updates FY25 guidance)
  • CDTX +7.5% (announces updates to its planned Phase 3 registrational trial of CD388 following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration)
  • QURE +3.1% (topline results from pivotal phase I/II study of AMT-130; entered into a $175 mln non-dilutive senior secured term loan facility with Hercules Capital)
  • CYBN +2.3% (highlights neuropsychiatry platform)
  • LCNB +2.2% (files for $100 mln mixed securities shelf offering)
  • DEFT +2% (launches thirteen new ETPs)
  • WNC +1.9% (partnership with Global Tank)
  • ABVX +1.9% (presentation of abstract for Obefazimod)
  • ACMR +1.9% (ACM Research (Shanghai) announces issuance report on private offering of ordinary shares)
  • PYPL +1.5% (PayPal and Blue Owl Capital announce execution of a two-year agreement under which funds managed by Blue Owl will purchase approximately $7 bln of buy now, pay later receivables originated by PayPal in the U.S)
  • GIFI +1.4% ($7 mln task order from Defense Logistics Agency)
  • CTO +1.4% (approves new $10 mln authorization; Completed $5 mln share repurchase program)
  • ORLA +1.3% (Announces that Newmont's (NEM) nominee Scott Langley has resigned from Orla's Board effective immediately) .

FT : Everyman defies cinema blues with velvet sofas and table service

Everyman defies cinema blues with velvet sofas and table service
Upmarket UK chain increases first-half revenues by more than a fifth as investments in premium experience pay off

Upmarket cinema chain Everyman increased its revenues by more than a fifth in the first half of the year, as the UK group bucked the trend of declining admissions by investing in table service and plush seating.

First-half revenues at Everyman, which offers cinemagoers velvet sofas and footrests, rose 21 per cent to £56.5mn, as admissions grew 15 per cent to 2.2mn.

The London-listed group has been a rare success in the wider cinema industry, which has struggled to recover from the pandemic and found it difficult to compete against the explosion in streaming services.

There were 127mn admissions to UK cinemas in 2024, down from 176mn in 2019, according to the UK Cinema Industry Association.

Everyman chief executive Alex Scrimgeour told the Financial Times that Everyman’s premium seating and dining options were central to its continued growth in the age of streaming.

Food and drinks, including the company’s new range of smashed burgers and its hibiscus strawberry daiquiri, are delivered directly to guests’ seats.

“A lot of people have good AV [audiovisual] equipment at home now: you need to do more than just show good films to get people out of their homes,” said Scrimgeour.

Everyman also boosted its revenues by increasing ticket prices by 6 per cent. The average price paid for a ticket to an Everyman cinema in the first half was £12.46 — more than 50 per cent higher than the industry average price, according to the UK Cinema Industry Association. Customers also spent an average of £11.09 each on food and drinks.

Despite healthy demand Everyman reported operating profits of just £102,000 in the first half, its first half-year profit since 2022, as a result of increased costs. The company’s shares were little changed on Wednesday morning.

Scrimgeour acknowledged that UK consumers were facing “a lot of uncertainty” but insisted that Everyman offered an “affordable luxury” that could still attract budget-conscious customers.

The cinema industry’s recovery from the pandemic was stalled by the US writers’ and actors’ strikes, which shut down production in Hollywood for six months in 2023.

Empire Cinemas and Cineworld both went into administration in 2023, and Cineworld said last year it would close 11 cinemas in the UK after agreeing a sweeping restructuring deal.

Everyman, by contrast, is continuing to expand, increasing its share of the UK cinema market to 5.8 per cent in the first half. The chain, which operates 49 cinemas, plans to open four further locations in 2026 and 2027.

Mark Photiades, an analyst at Canaccord Genuity, said he was optimistic that Everyman had “plenty of further UK expansion potential” for its “differentiated and elevated brand offer”.

The pipeline of major studio releases is finally “akin to the pre-pandemic film slate for the first time”, said Scrimgeour.

He referenced the upcoming release of Universal’s Wicked: For Good. The first instalment of the musical was the UK’s highest-grossing film in 2024, netting £59.6mn.

FT : Activist Engine Capital builds stake in mental health group under federal i

Activist Engine Capital builds stake in mental health group under federal investigation
Hedge fund takes 3% of Acadia Healthcare amid probe by US justice department and SEC

Activist hedge fund Engine Capital has built a stake in one of America’s largest providers of mental health services, arguing that it needs a board refresh as it faces multiple federal probes.

Engine revealed its roughly 3 per cent stake in Acadia Healthcare in a letter to the board, seen by the Financial Times, which called for the company to review its asset portfolio, improve its board directors and halt capital-intensive projects for new facilities.

Engine’s move, which puts it among Acadia’s 10 biggest investors, came as the behavioural health company faces Department of Justice and Securities and Exchange Commission investigations into allegations of holding patients against their will and falsifying insurance claims.

Shares in Acadia, which operates more than 250 facilities nationwide, including psychiatric hospitals and opioid recovery clinics, are down 71 per cent over the past year, giving it an equity value of just over $2bn.

The company first told investors about the government probes last autumn. They cost it $84.5mn in legal costs in the first six months of this year.

Acadia did not immediately respond to requests for comment. Engine declined to comment.

In the letter, Engine accused Acadia of maintaining a “growth at any cost” approach that has given rise to a bloated corporate structure. It also wrote that a 2022 reorganisation left it with an unwieldy management structure that has stifled the company’s turnaround.

Engine called for the Tennessee-based company to add new directors with expertise in behavioural health and capital allocation.

“It is stunning that Acadia’s board does not have a single director with relevant operating experience,” Engine wrote in its letter to the board. It also encouraged the company to consider asset sales to free up cash to buy its “deeply undervalued” shares.

On an earnings call last month, Acadia’s chief executive Chris Hunter said he was “pleased” with the company’s progress. Hunter, a former executive at heath insurance group Humana, has led the company since 2022.

Hunter added that “we’re committing to and have been committed to conducting a very thorough and independent review of our operations, while continuing to work very cooperatively with the DOJ and the SEC”. Acadia has already struck several settlements with authorities in past cases.

Founded in 2013 by Arnaud Ajdler, Engine Capital has targeted a wide array of companies, including industrials group Flowserve, oil and gas company Parkland Corporation and most recently diagnostics group Avantor.

Engine has claimed several victories this year. UK engineering business Smiths Group conceded to its calls for a break-up. Lyft made changes to its board and dual-class share structure not long after the hedge fund ended a campaign for these moves.

>>> Cidara Therapeutics announces updates to its planned Phase 3 registrational

Cidara Therapeutics announces updates to its planned Phase 3 registrational trial of CD388 following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration
  • Update based on FDA End-of- Phase 2 meeting outcome.
  • Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season.
  • A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval.
  • Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status.

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • LAC +61.6%, CLCO +19%, BABA +9.4%, THO +5.6%, GIFI +5.2%, MLKN +2.9%, DEFT +2.4%, CYBN +2.3%, ABVX +2.3%, LCNB +2.2%, WNC +1.9%, WFRD +1.7%, VOXR +0.8%, EVH +0.7%, ALGN +0.7%, BYD +0.6%, MU +0.6%
  • Gapping down:
    • COHU -9.2%, AGEN -3.2%, CTRE -3%, AZN -1.2%, NVS -0.5%

>>> Europe : Brokers Upgrades & Downgrades - 24th of September 2025 V2(+)

>>> Up
* AB Foods Raised to Hold at Deutsche Bank; PT 2,000 pence
* Anglogold Raised to Overweight at ABSA Securities; PT $91.58
* Bechtle Raised to Outperform at BNPP Exane; PT 47 euros
* Bouygues Raised to Equal-Weight at Morgan Stanley; PT 44 euros
* Cancom Raised to Neutral at BNPP Exane; PT 25 euros
* Equinor Raised to Buy at ABG; PT 300 kroner
* General Motors Raised to Buy at UBS; PT $81
* Micron Raised to Outperform at KGI Securities; PT $196
* Orlen Raised to Outperform at Santander Biuro Maklerskie (+)
* Vor BioPharma Raised to Buy at Stifel; PT $55

>>> Down
* Commerzbank Cut to Underperform by Keefe, Bruyette & Woods
* Deutsche PBB PT Cut to 4.40 euros at Bankhaus Metzler (+)
* Evonik Cut to Hold at Deutsche Bank; PT 16 euros
* Exail Technologies Cut to Hold at TP ICAP Midcap; PT 95 euros (+)
* Lanxess Cut to Hold at Deutsche Bank; PT 23 euros
* NCAB Group Cut to Hold at SEB Equities; PT 54 kronor
* Porsche Cut to Sell at Bankhaus Metzler; PT 31 euros
* Sats Cut to Hold at ABG; PT 42 kroner
* Swiss Re Cut to Neutral at JPMorgan; PT 160 Swiss francs

>>> Initiation
* C&C Rated New Sector Perform at RBC; PT 160 pence
* Georgia Capital Rated New Outperform at KBW; PT 3,400 pence
* Lion Finance Group Rated New Outperform at KBW; PT 9,400 pence
* Orsero Rated New Buy at TP ICAP Midcap; PT 26.30 euros (+)
* Siegfried Rated New Hold at Kepler Cheuvreux; PT 92 Swiss francs (+)
* Var Energi Rated New Buy at Citi; PT 46 kroner

>>> Call
* General Motors Raised to Buy at UBS on Improving Margin Outlook
* JPMorgan Sees Reinsurance Market to Soften in 2026, Swiss Re Cut
* Porsche’s Valuation Seems Challenging, Bankhaus Metzler Cuts (+)
* Var Energi Initiated Buy at Citi, Top Pick Among European E&Ps